Kedrion Biopharma
Filippo Mori is a senior research specialist at Kedrion Biopharma, where involvement in plasma protein purification includes managing technical documentation, reporting, process scale-up, and advanced statistical data analysis. As the Open Innovation Lead, responsibilities encompass managing personnel, evaluating projects from research institutions, and overseeing contract manufacturing and partner relations. With a solid background in process development and regulatory compliance from previous roles, including laboratory supervisor and principal researcher, Filippo has developed analytical assays and applied Good Manufacturing Practices in the biopharmaceutical sector. Educational qualifications include a specialization in clinical biochemistry and a degree in pharmaceutical chemistry and technology from the University of Pisa.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.